
Releases
Simcere Pharmaceutical Partners with Stanford to Combat Pulmonary Fibrosis
Simcere Pharmaceutical has signed a research agreement with Stanford Medicine to develop a first-in-class molecule targeting idiopathic pulmonary fibrosis. The collaboration aims to address a condition that currently limits patient survival to a median of three years, leveraging specialized expertise from Stanford’s chemical biology laboratories.
























